(tert-Butoxymethylidene)cyclopropane | 23230-90-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (tert-Butoxymethylidene)cyclopropane
• 英文别名: (2-methylpropan-2-yl)oxymethylidenecyclopropane
• CAS: 23230-90-2
• 化学式: C₈H₁₄O
• 分子量: 126.2
• InChiKey: HTNYPZRNCTWUTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• [EN] NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION<br/>[FR] NOUVEAUX INHIBITEURS MACROCYCLIQUES DE LA MULTIPLICATION DU VIRUS DE L'HÉPATITE C
  申请人：INTERMUNE INC

  公开号：WO2007015824A2

  公开（公告）日：2007-02-08

  [EN] The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.
  [FR] La présente invention concerne des composés de la formule générale (I) à la formule générale (VIII), ainsi que des compositions, comprenant des compositions pharmaceutiques, comprenant un composé sujet. La présente invention concerne également des procédés de traitement, comprenant des procédés de traitement de l'infection par le virus de l'hépatite C et des procédés de traitement de la fibrose hépatique, les procédés impliquant généralement l'administration à un individu nécessitant celle-ci une quantité efficace d'un composé ou d'une composition sujet.
• [EN] SELECTIVE CYSTEINE PROTEASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS SÉLECTIFS DE CYSTÉINE PROTÉASE ET LEURS UTILISATIONS
  申请人：NEW WORLD LAB INC

  公开号：WO2012140500A1

  公开（公告）日：2012-10-18

  The present invention relates to compounds of Formula I, II, IA-VA, IVA1-1VA5, 11IA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1 -IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease).